Brii BioSciences competitors

Founder of Sirius XM radio and United Therapeutics. Progressive technologist and green energy advocate. Helicopter, fixed wing pilot.

Michael Gilman, Ph.D. has served as a member of our board of directors since November 2013. Michael Gilman is currently Chairman and Chief Executive Officer for Arrakis Therapeutics, Inc., a role he has served in since 2016, and Chief Executive Officer and Director for Obsidian Therapeutics, Inc., a role he has served in since 2016. Previously, from 2014 to 2016 Michael Gilman was Founder and Chief Executive Officer of Padlock Therapeutics, Inc. Prior to Padlock, Michael Gilman served as Senior Vice President, Early-Stage Pipeline, at Biogen Idec Inc. from 2012 to 2013. He joined Biogen Idec Inc. in 2012 following its acquisition of Stromedix, Inc., where he was Founder and Chief Executive Officer. Prior to founding Stromedix in 2006, from 1999 to 2005, Michael Gilman served in a variety of capacities, most recently as Executive Vice President, Research at Biogen Idec. From 1994 to 1999, Michael Gilman was at ARIAD Pharmaceuticals, Inc., where he was Executive Vice President and Chief Scientific Officer. From 1986 to 1994, Michael Gilman was on the scientific staff of Cold Spring Harbor Laboratory in New York. He also serves on the Board of Directors of X4 Pharmaceuticals, Inc. and the Scientific Advisory Board of FutuRx, an Israeli biotech accelerator. Michael Gilman was a postdoctoral fellow with Dr. Robert Weinberg at the Whitehead Institute. He holds a Ph.D. in Biochemistry from University of California, Berkeley, and an S.B. in Life Sciences from Massachusetts Institute of Technology.

• Member of the National Ernst and Young Entrepreneur of the Year Hall of Fame• Inducted into the University of Texas College of Natural Sciences Hall of Honor• Received Ohio University's School of Business Distinguished Business Award• Received Ohio University Konneker Medal, the highest award given to a faculty member or former student for entrepreneurial excellence• Named one of the top 10 Life Sciences CEOs in Texas by the Texas Healthcare and Bioscience InstituteMr. Hawkins is currently the President and CEO of Lumos Pharma, Inc. an early-stage orphan drug company based in Austin, Texas. He currently serves as a Board of Director for SciClone Pharmaceuticals Inc., a NASDAQ listed company (SCLN), a biopharmaceutical company whose lead product Zadaxin, an adjuvant for the influenza vaccine in immunocompromised patients or as an immune stimulant, has been approved in at least 13 countries.In addition he serves as a Board of Director for Cytori Therapeutics, Inc.; a global leader in stem cell research and the use of adipose derived stem and regenerative cells.Rick Hawkins is a member of the National Ernst and Young Entrepreneur of the Year Hall of Fame.Mr. Hawkins was inducted into the Hall of Honor for the College of Natural Sciences at the University of Texas by Dean, Mary Ann Rankin. In 2006 he received Ohio University’s Distinguished Business Achievement Award, and in 2014 was awarded the Konneker Medal, the leading entrepreneurial honor awarded by the University. Rick was named one the top 10 Life Sciences CEO’s in Texas by the Texas Healthcare & Bioscience Institute and was the keynote speaker at BioVenture Showcase 2008.

Imran Alibhai is a Board Member at Tvardi Therapeutics and Chief Executive Officer at Tvardi Therapeutics. He has worked as Sr VP/Managing Director at DNAtrix Inc and Executive at ISB Accelerator Corp. Imran works or has worked at MPM Capital.